Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia
- PMID: 11330878
- DOI: 10.1097/00004872-200104000-00012
Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia
Abstract
Objective: In hypertriglyceridemic patients, hypertension occurs frequently and may be associated with hyperinsulinemia and elevated plasma levels of free fatty acids (FFA). Besides the lipid-lowering effects, fibrates have been shown to reduce blood pressure in hypertensive patients. The present study was undertaken to investigate the effects of bezafibrate on hemodynamics in relation to insulin, FFA, sympathetic activity, renal sodium absorption, cyclic-GMP (cGMP) and endothelin-1 in hypertriglyceridemic patients.
Subjects and methods: Hypertriglyceridemic patients (17) were randomized to receive in a double-blind placebo-controlled study bezafibrate or placebo for 6 weeks. At the end of both treatment periods, blood pressure and heart rate were measured automatically. Plasma insulin, FFA, aldosterone, catecholamines, cGMP, endothelin-1 levels and 24 h urine catecholamines and sodium excretion were assessed.
Results: Bezafibrate therapy decreased serum triglycerides (-65%, P < 0.001) and hemodynamic parameters: heart rate decreased from 69 to 66/min (P = 0.009), systolic blood pressure from 137 to 132 mmHg (P = 0.01), diastolic blood pressure from 81 to 79 mmHg (P = 0.07) and mean blood pressure from 102 to 99 mmHg (P = 0.06). Bezafibrate therapy reduced FFA and insulin (-55 and -57% respectively, both P < 0.001), while sympathetic activity and renal sodium absorption were not affected. cGMP increased (+17%, P = 0.008), whereas endothelin-1 levels tended to decrease upon bezafibrate therapy (-10%, P = 0.077)
Conclusion: Bezafibrate reduces heart rate, blood pressure, insulin and FFA in hypertriglyceridemic patients. The hemodynamic effects cannot be attributed to changes in sympathetic activity or renal sodium absorption. Instead, based on the increase in plasma cGMP levels, the bezafibrate-induced hemodynamic effects are most likely to be caused by bezafibrate-induced improvement of endothelial function.
Comment in
-
Antihypertensive mechanisms of lipid-lowering drugs: decoding the Rosetta stone's inscriptions'.J Hypertens. 2001 Apr;19(4):675-7. doi: 10.1097/00004872-200104000-00002. J Hypertens. 2001. PMID: 11330868 Review. No abstract available.
Similar articles
-
Bezafibrate improves hypertension and insulin sensitivity in humans.Hypertens Res. 2003 Apr;26(4):307-13. doi: 10.1291/hypres.26.307. Hypertens Res. 2003. PMID: 12733699 Clinical Trial.
-
Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.Am J Med. 2002 Mar;112(4):275-80. doi: 10.1016/s0002-9343(01)01123-8. Am J Med. 2002. PMID: 11893366 Clinical Trial.
-
Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):307-13. doi: 10.1161/01.atv.0000046230.02211.b4. Arterioscler Thromb Vasc Biol. 2003. PMID: 12588776 Clinical Trial.
-
Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).Eur Heart J. 1996 Dec;17 Suppl F:37-42. doi: 10.1093/eurheartj/17.suppl_f.37. Eur Heart J. 1996. PMID: 8960446 Review.
-
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.Drugs. 1996 Nov;52(5):725-53. doi: 10.2165/00003495-199652050-00008. Drugs. 1996. PMID: 9118820 Review.
Cited by
-
Dyslipidemia Increases the Risk of Incident Hypertension in a Large Taiwanese Population Follow-Up Study.Nutrients. 2022 Aug 10;14(16):3277. doi: 10.3390/nu14163277. Nutrients. 2022. PMID: 36014784 Free PMC article.
-
Barth Syndrome Cardiomyopathy: An Update.Genes (Basel). 2022 Apr 8;13(4):656. doi: 10.3390/genes13040656. Genes (Basel). 2022. PMID: 35456462 Free PMC article. Review.
-
HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models.J Clin Invest. 2022 Apr 15;132(8):e131053. doi: 10.1172/JCI131053. J Clin Invest. 2022. PMID: 35230976 Free PMC article.
-
The Interplay between Non-Esterified Fatty Acids and Plasma Zinc and Its Influence on Thrombotic Risk in Obesity and Type 2 Diabetes.Int J Mol Sci. 2021 Sep 20;22(18):10140. doi: 10.3390/ijms221810140. Int J Mol Sci. 2021. PMID: 34576303 Free PMC article. Review.
-
Treatment With Gemfibrozil Prevents the Progression of Chronic Kidney Disease in Obese Dahl Salt-Sensitive Rats.Front Physiol. 2020 Sep 18;11:566403. doi: 10.3389/fphys.2020.566403. eCollection 2020. Front Physiol. 2020. PMID: 33071820 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical